Aslani, Iris .

HRN: 24-25-40  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/13/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/13/2024
05/20/2024
IV
40
Q12
PCAP, T/C CNS Infection
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft TissueCentral Nervous System    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: